Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Diagnostic or test agent produces visible change on skin
Reexamination Certificate
2004-12-22
2010-02-02
Gabel, Gailene R. (Department: 1641)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Diagnostic or test agent produces visible change on skin
C424S009100, C424S009200, C424S009800, C424S248100, C424S443000, C424S810000, C235S2010FS, C235S2010FS
Reexamination Certificate
active
07655218
ABSTRACT:
Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a mycobacterium but are without active disease, or those who have been vaccinated with BCG. The methods comprise topical application of antigen compositions for transdermal delivery.
REFERENCES:
patent: 4965192 (1990-10-01), Maes
patent: 5496819 (1996-03-01), Okuyama et al.
patent: 5709879 (1998-01-01), Barchfeld et al.
patent: 6120776 (2000-09-01), Haslov et al.
patent: 0199362 (1986-04-01), None
patent: 01-243997 (1989-09-01), None
patent: 06-169758 (1994-06-01), None
patent: 9206092 (1997-08-01), None
patent: 09206092 (1997-08-01), None
patent: 09206092 (1997-12-01), None
patent: WO 95/01440 (1995-01-01), None
patent: WO 95/34328 (1995-12-01), None
patent: WO 96/40236 (1996-12-01), None
Haga, et al., Difference in Delay Skin Reaction to MPB64 Between BCG-Immunized and Tubercle Baccil-Infected Guinea Pigs,Tubercle and Lung Disease, vol. 75, Supplement 1, p. 54, 28thWorld Conference of IUATLD/UICTMR, Mainz, Germany, Jun. 14-17, 1994.
Haga, et al., Effective Isolation of MPB64 from a Large Volume of Culture Filtrate ofMycobacterium bovisBCG Tokyo,JPN. J. Med. Sci. Biol., vol. 49, pp. 15-27 (1996).
Haga et al., Delayed Type Hypersensitivity to a recombinant mycobacterial antigen, MPB64, in guinea pigs sensitized toMycobacterium tuberculosisorMycobacterium bovisBCG,Journal of Leukocyte Biology, vol. 57, pp. 221-225 (1995).
Nakamura, et al., Tuberculosis Diagnosis with MPB64—Preliminary Study with a human being, “Kekkeku (Tuberculosis)”,The Japanese Society for Tuberculosis, Feb. 15, 2996. Discusses results of preliminary studies conducted to test efficacy of MPB64 antigen administered to skin surface by way of hydrophilic ointment. Results were inconclusive and ointment was not defined.
Wilcke, et al., Clinical Evaluation of MPT-64 and MPT-59, two proteins secreted fromMycobacterium tuberculosis, for skin test reagents,Tubercule and Lung Disease, vol. 77, pp. 250-256 (1996).
Harboe et al., “Properties of Proteins MPB64, MPB70, and MPB80 ofMycobacterium bovisBCG”, Infection and Immunity, vol. 52, No. 1, p. 293-302, 1986.
Nagai et al., “Specific Skin-Reactive Protein from Culture Filtrate ofMycobacterium bovisBCG”, Infection and Immunity, vol. 31, No. 1, p. 1152-1160, 1981.
Wiker et al., “MPB59, a Widely Cross-Reacting Protein ofMycobacterium bovisBCG”, Int. Archs Allergy appl. Immun., vol. 81, No. 4, p. 307-314, 1986.
Gabel Gailene R.
Japan BCG Laboratory
King & Spalding
LandOfFree
Methods and compositions for detection and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for detection and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for detection and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4205149